WinstonWınston
Back
Stock

Xeris Biopharma Holdings

XERS
38
Biotechnology · Healthcare
Also trades as: 0A8E.L GBP 0.10 (-6.55%)
Price
$10.20
-0.66 (-6.08%)
Market Cap
$1.86B
Exchange
NASDAQ
Winston Score
38
Winston is serious
Below-average fundamentals — multiple weak pillars.
Data as of Oct 24, 2026 · filings through Jun 30, 2026

§How the score breaks down

Quality
Mixed
13/30
Growth
Good
12/20
Cash Flow
Mixed
3/10
Stability
Weak
2/10
Valuation
Data not available
0/10
Ownership
Mixed
6/15
Dividends
Not counted
n/a

36 of 95 counted points = Winston Score 38. Pillars marked n/a do not apply to this company and are left out of the total.

Track this stock — start free trial

Share count rising — dilution

+118.6% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 79.0M (2021) → 172.7M (2025)

§Winston Score History

The full picture

Xeris Biopharma is a specialty pharmaceutical company that makes ready-to-use injectable medicines for people with serious hormonal and metabolic conditions. Its main products include Gvoke, a glucagon rescue pen for people with diabetes who experience dangerously low blood sugar, and Recorlev, a treatment for Cushing's syndrome, a rare hormonal disorder. The company also sells Ogluo, a glucagon product marketed in Europe.

Xeris earns money by selling these prescription drugs directly to patients through pharmacies and specialty distributors, primarily in the United States and the United Kingdom. The company is relatively small, with annual revenues in the low hundreds of millions of dollars, and its edge comes from proprietary formulation technology that keeps certain drugs stable in liquid form without refrigeration. The key risk is that Xeris carries significant debt and must grow its commercial products fast enough to reach profitability, which remains a challenge for small specialty pharma companies competing against larger, better-funded rivals.

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+28.7% YoY

YoY Growth Rate

Strong revenue growth

Reported EPS Growth

<−1,000% YoY

Quarterly reporting periods ended:

30 Jun 2025: $-0.0121

30 Jun 2026: $-0.18

Reported/statutory EPS, not adjusted or underlying earnings. One-off items can affect this figure. Provider rounding can affect the growth rate.

YoY Growth Rate

Reported EPS decreased year over year

R&D Spend

$31M/ year

↑ Rising (+22% vs prior year)

10.7% of revenue

Below sector average (18%)

Investing heavily in future products and technology

Insider Activity

4.6%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Position

Cash flow positive

$122M cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Company generates more cash than it spends — no dilution risk from fundraising

Strong grower

Xeris Biopharma Holdings is growing revenue at 29% year-over-year. The Winston Score penalises unprofitable companies, but revenue at this pace tells a different story — this is a company still in "build mode."

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale
Gross Margin
86.4%
Premium pricing power — 86.4% gross margin
Profit after running costs
Operating Margin
5.6%
Thin — 5.6% operating margin
Return on the money invested
ROCE
1.8%
Weak — 1.8% return on capital

ROIC between 0% and 5%. They earn a few cents back per dollar invested in the business.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth
Sales YoY
+36.3%
Fast-growing sales (+36.3% YoY)
Profit growth
EPS YoY
N/A
—
Data not available
How steady the profit is
EPS Consistency
6/8 quarters
Earnings grew in most of the last 8 quarters

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash
Cash Conversion
N/A
Data not available
Spare cash per sale
FCF Margin
16.5%
Converts sales into free cash efficiently (16.5%)

FCF margin between 10% and 20%. Every $100 in sales becomes $10 to $20 in real cash.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns
Debt / Equity
2.87
Heavy debt load (2.87)
Covers its interest
Interest Cover
1.30x
Dangerous — barely covers interest (1.3x)

Interest coverage between 1 and 3. Profits cover interest, but with little room to spare.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit
P/E Ratio (TTM)
N/M
Negative earnings — P/E not meaningful
Cheaper or dearer next year
P/E vs Forward
N/A
not available
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial